Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.08) per share. This is a 96.21 percent increase over losses of $(2.11) per share from the same period last year.
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation In China
LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the National